MarginsXMarginsX
Home › Markets › Health Care › NRXP

NRX Pharmaceuticals Inc. (NRXP)

NRXP trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$2.15
-1.83% on the day
Market cap
$93.8M
Micro cap
Revenue · 2025
$1.2M
Prior year not contiguous
Net income · 2025
-$28.6M
-2336.5% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1719406/000143774926009418/0001437749-26-009418-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerNRXP on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2017
SEC CIK0001719406
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$1.2M
Net income-$28.6M
Operating income-$16.2M
Net margin-2336.5%
Operating margin-1324.4%
Revenue growthNo prior-year revenue to compare
Cash$7.8M
Total assets$13.0M
P/E (computed)Net income was not positive
P/S (computed)76.6×

Warning signs

Cash runway
16.2 months
$26.7M cash at June 30, 2026
Share count, 1 year
+119.7%
2025-08-14 to 2026-08-14 · +429.9% over 3 years
Going-concern doubt
Yes
10-Q filed August 14, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"As such, the Company has concluded that substantial doubt exists regarding the Company's ability to continue as a going concern for a period of at least twelve months from the date of issuance of these consolidated financial statements."
10-Q 2026-08-14
Cash and burn$26.7M cash; operating cash flow -$4.9M a quarter.Report 2026-06-30
Shares outstanding43,295,767 (2026-08-14); 19,705,077 a year earlier; 81,700,918 three years earlier. 3y figure adjusted for split (1-for-10 overall).Cover page 2026-08-14
Reverse splits, 3 years1; latest 1-for-10 on 2024-04-02Source 2024-04-02
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the marketLatest 2026-06-03
Exchange deficiency notices, 12 months1 (8-K item 3.01)8-K 2026-01-16
Delisting25-NSE filed25-NSE 2026-05-22
AuditorWeinberg & Company, P.A., Los Angeles, California, United States; changed auditors 1 time in 24 months8-K 4.01 2025-11-26
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
$1.1M-$16.5M-$8.9M$26.7M$412K$3.4M10-Q 2026-08-14
Q1 2026
2026-03-31
$1.1M-$1.4M-$4.3M$6.7MNo debt tags$2.3M10-Q 2026-05-15
Q4 2025
2025-12-31
$983K$360K-$3.7M$7.8M$0$1.2M10-K 2026-03-23
Q3 2025
2025-09-30
$242K-$5.9M-$2.9M$7.2M$10.1M$242K10-Q 2025-11-14
Q2 2025
2025-06-30
$0-$17.6M-$4.0M$2.9M$10.2M$010-Q 2026-08-14
Q1 2025
2025-03-31
$0-$5.5M-$3.5M$5.5M$8.4MNeeds four quarters10-Q 2026-05-15
Q4 2024
2024-12-31
$0-$9.1M-$2.1M$1.4M$1.6M$010-K 2026-03-23
Q3 2024
2024-09-30
$0-$1.6M-$2.3M$1.6M$3.7MNeeds four quarters10-Q 2025-11-14

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
FORM 424B5
424B52026-06-03
Latest annual report
FORM 10-K
10-K2026-03-23
Latest quarterly / interim
FORM 10-Q
10-Q2026-11-16
Latest current report
FORM 8-K
8-K2026-11-02
Latest proxy
FORM DEFA14A
DEFA14A2026-11-05

Source: SEC EDGAR submissions feed, 480 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-8.0%
1 month-18.9%
3 months-34.4%
Year to date-19.2%
1 year-15.4%
From 52-week high-52.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
EQEquillium Inc.$1.15-10.85%$94.7M
NBPNovaBridge Biosciences$0.7915-6.87%$91.3M
RTSNRetension Pharmaceuticals Inc.$11.46-6.60%$90.3M
PMVPPMV Pharmaceuticals Inc.$1.19-6.30%$89.9M
ANIXAnixa Biosciences Inc.$2.55-2.67%$88.6M
HURATuHURA Biosciences Inc.$1.33-4.32%$87.5M
KZIAKazia Therapeutics Limited$5.60-15.41%$87.1M
GNLXGenelux Corporation$1.92+2.95%$86.9M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier